Table 2.
Positivity of cancer-associated genes in peripheral blood and bone marrow specimens
|
PBLN (n = 49) Ave. ΔCt (S.Dev.) |
PBLBRCA (n = 215) Positivity* (%) |
BMN (n = 49) Ave. ΔCt (S.Dev.) |
BMBRCA (n = 177) Positivity* (%) |
|
| Mam | 24.00 (0.00) | 29 (13.5%) | 22.00 (0.00) | 7 (4.0%) |
| PIP | 25.84 (0.55) | 36 (16.7%) | 22.43 (1.37) | 5 (2.8%) |
| CEA | 23.88 (0.65) | 51 (23.7%) | 21.16 (2.84) | 2 (1.1%) |
| PSE | 22.60 (2.44) | 58 (27.0%) | 16.98 (1.50) | 5 (2.8%) |
| CK19 | 21.41 (5.03) | 0 (0%) | 15.53 (5.11) | 0 (0%) |
| Muc1 | 13.90 (2.11) | 0 (0%) | 6.77 (1.12) | 0 (0%) |
| ErbB2 | - | - | 8.91 (2.38) | 0 (0%) |
| EpCAM | 21.40 (1.97) | 7 (3.3%) | - | - |
| Gene panel | - | 136 (63.3%) | - | 19 (10.7%) |
* ΔCt threshold was set 3 standard deviations from the mean in normal samples